|
08 Dec 2020 |
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
|
|
08 Dec 2020 |
Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma
|
|
08 Dec 2020 |
Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American Society of Hematology (ASH) Meeting
|
|
08 Dec 2020 |
Triphase Accelerator Announces Positive Interim Results of Phase 1 Trial of TRPH-222 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
|
|
08 Dec 2020 |
Roche presents new data from its bispecific antibody portfolio across a range of blood cancers
|
|
08 Dec 2020 |
Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma
|
|
08 Dec 2020 |
Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer
|
|
08 Dec 2020 |
Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent in Patients with SCID Undergoing Hematopoietic Cell Transplantation
|
|
07 Dec 2020 |
MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
|
|
07 Dec 2020 |
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
|
|
06 Dec 2020 |
IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting
|
|
06 Dec 2020 |
Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
|
|
06 Dec 2020 |
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
|
|
06 Dec 2020 |
Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
|
|
06 Dec 2020 |
Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020
|
|
05 Dec 2020 |
Data from the APOLLO Study Show Clinically Meaningful Response with DARZALEX®▼ (daratumumab) Subcutaneous Formulation Regimen After First or Subsequent Relapse in Multiple Myeloma
|
|
04 Dec 2020 |
F-star Therapeutics Announces First Patient Dosed in First-in-Class FS120 Phase 1 Clinical Trial
|
|
04 Dec 2020 |
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
|
|
04 Dec 2020 |
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study
|
|
04 Dec 2020 |
Approved IND for Alligator Bioscience's CD40-targeting antibody mitazalimab
|
|
03 Dec 2020 |
Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
|
|
03 Dec 2020 |
Memo Therapeutics AG’s Antibody Against SARS-CoV-2 Demonstrates Potent Therapeutic and Prophylactic Activity in Advanced COVID-19 Disease Model
|
|
02 Dec 2020 |
Obiltoxaximab Receives Marketing Authorization From European Commission For The Treatment Of Inhalation Anthrax
|
|
02 Dec 2020 |
Genentech Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal Polyps
|
|
02 Dec 2020 |
Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
|
